Jacqueline Bork

Dr. Jacqueline Bork

Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
JBJacqueline Bork
Jacqueline Bork
EHEmily L. Heil
Emily L. Heil
SBShanna Berry
Shanna Berry
ELEurides Lopes
Eurides Lopes
RDRohini Davé
Rohini Davé
AAAnthony Amoroso
Anthony Amoroso
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections. Importantly, dalbavancin’s real benefits may be in treating complicated infections in vulnerable patient populations, such as persons who inject drugs (PWID). Methods A multicenter retrospective analysis was performed from March 2014 to April 2017 to assess 30- and 90-day clinical cure and adverse drug events (ADEs) in adult patients who received ≥ 1 dose of dalbavancin for a non-ABSSSI indication. Results During the study period, 45 patients received dalbavancin, 28 for a non-ABSSSI indication. The predominant infections treated included osteomyelitis (46%), endovascular infection (25%) and uncomplicated bacteremia (14%). Half of the patients had positive Staphylococcus aureus in cultures, 29% methicillin resistant and 21% methicillin susceptible. Most patients were prescribed dalbavancin as sequential treatment with a median of 13.5 days of prior antibiotic therapy. The most common reason for choosing dalbavancin over standard therapy use was PWID (54%). Seven patients were lost to follow-up at day 30. Of the remaining evaluable patients, 30-day clinical cure was achieved in 15/21 (71%) patients. The most common reason for failure was lack of source control (4/6, 67%). At day 90, relapse occurred in two patients. Three patients had a potential dalbavancin-associated ADE: two patients with renal dysfunction and one patient with pruritus. Conclusions This study demonstrates a possible role for dalbavancin in the treatment of non-ABSSSI invasive gram-positive infections in select vulnerable OPAT patients.

10 December 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
JBJacqueline Bork
Jacqueline Bork
SLSurbhi Leekha
Surbhi Leekha
KCKimberly Claeys
Kimberly Claeys
HSHyunuk Seung
Hyunuk Seung
MTMegan Tripoli
Megan Tripoli
EHEmily L. Heil
Emily L. Heil
Interrupted time series segmented regression was conducted to trend antibiotic use and multidrug-resistant gram-negative (MDRGN) acquisition relative to COVID-19 in an academic hospital. Total antibiotic use and antibiotic use related to pneumonia was higher in the period after the onset of COVID-19 compared to the similar calendar period in 2019. Furthermore, MDRGN acquisition increased 3% for every increase in positive COVID-19 tests per week.

4 July 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SSStephanie Shulder
Stephanie Shulder
PTPranita D Tamma
Pranita D Tamma
SFSuiyini Fiawoo
Suiyini Fiawoo
KDKathryn Dzintars
Kathryn Dzintars
DEDaniel Escobar
Daniel Escobar
JBJacqueline Bork
Jacqueline Bork
Gram-negative bacteremia (GN-BSI) can cause significant morbidity and mortality, but the benefit of infectious diseases consultation (IDC) is not well defined. A 24-site observational cohort study of unique hospitalized patients with 4861 GN-BSI episodes demonstrated a 40% decreased risk of 30-day mortality in patients with IDC compared to those without IDC.

22 July 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JBJacqueline Bork
Jacqueline Bork
KCKimberly C. Claeys
Kimberly C. Claeys
EHEmily L. Heil
Emily L. Heil
MBMary Banoub
Mary Banoub
SLSurbhi Leekha
Surbhi Leekha
MKMichael Kleinberg
Michael Kleinberg
Hospital-based antibiotic stewardship (AS) programs provide oversight and guidance for appropriate antimicrobial use in acute care settings. Infectious disease expertise is beneficial in the care of hospitalized patients with infections. The impact of infectious diseases consultation (IDC) on antimicrobial appropriateness in a large tertiary hospital with an established AS program was investigated. This was a cross-sectional study from October 2017 to March 2019 at a large academic hospital with an AS-directed prospective audit and feedback process and multiple IDC services.

1 March 2021 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
NHNaomi Hauser
Naomi Hauser
JKJustin J. Kim
Justin J. Kim
PLPaul M. Luethy
Paul M. Luethy
SSSarah A. Schmalzle
Sarah A. Schmalzle
JBJacqueline Bork
Jacqueline Bork

1 August 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EHEmily L Heil
Emily L Heil
JJJulie Ann Justo
Julie Ann Justo
JBJacqueline Bork
Jacqueline Bork
Inpatient antimicrobial stewardship (AS) programs are quality improvement programs tasked with improving antibiotic practices by augmenting frontline providers’ antibiotic prescription. Prospective audit and feedback (PAF) and preauthorization (PRA) are essential activities in the hospital that can be resource intensive for AS teams. Improving efficiency in AS activities is needed when there are limited resources or when programs are looking to expand tasks beyond PAF and PRA, such as broad education or guideline development. Guidance on the creation and maintenance of alerts for the purpose of PAF reviews, modifications of antibiotic restrictions for PRA polices, and overall initiative prioritization strategies are reviewed. In addition, daily prioritization tools, such as the tiered approach, scoring systems, and regression modeling, are available for stewards to prioritize their daily workflow. Using these tools and guidance, AS programs can be productive and impactful in the face of resource limitation or competing priorities in the hospital.